New Micro Device Injects a Boost to IVF Success
Adelaide, Australia - 12 May 2022: A research team led by the University of Adelaide, in partnership with medical technology company Fertilis, has delivered a ground-breaking new micro-device to streamline the only fertility treatment procedure available for men with low sperm counts.
The first-of-its-kind device will allow more IVF clinics to offer Intracytoplasmic Sperm Injection (ICSI) as a treatment, while several IVF procedures, such as embryo culture, embryo cryopreservation and in vitro maturation, will also be improved by using the device. ICSI is a slow and difficult procedure which involves the injection of a single sperm into an egg for fertilisation, and it can only be carried out by experienced embryologists.
This new technology – smaller than a pinhead in size - holds up to 10 eggs in segregated positions for quicker injection, making it easier for embryologists to track and avoid the risk of errors.
Lead researcher Dr Kylie Dunning, from the University of Adelaide’s Robinson Research Institute, said the device will cut treatment time in half, require less training for embryologists with less expensive equipment than current ICSI treatment and improve access to the procedure for more patients.
“The development of this new, innovative approach is an important breakthrough for people wanting to start a family who haven’t been able to due to male infertility,” Dr Dunning said. “By removing the need for the pipette that normally holds the unfertilised egg in position during ICSI, this device simplifies the injection process, reduces dependency on a high level of technical experience and will dramatically improve embryo production. This discovery removes significant barriers to treatment for people with infertility and will improve IVF success.”
Device inventor and Fertilis co-founder Professor Jeremy Thompson said his company is excited to bring the breakthrough device to market. “Where IVF science has excelled, technology has tended to stagnate - until now,” Professor Thompson said. “ICSI hasn’t changed since its discovery 30 years ago. Continued innovation in the IVF lab like this is the only way we will boost success and reduce the financial and emotional burden for patients.”
The device will undergo global clinical trials in 2022.
This cutting-edge development would not have been possible without the support of the Australian Research Council and The Hospital Research Foundation Group. Paul Flynn, Chief Executive Officer of the Hospital Research Foundation Group, said the organisation has been proud to support Dr Dunning’s research during the past three years to improve IVF success rates.
“This device is set to be a game changer for thousands of hopeful parents who need to rely on ICSI,” Mr Flynn said.
Primary author, Suliman Yagoub, is a PhD candidate in the School of Biomedicine at The University of Adelaide.
Professor Kishan Dholakia from the University of Adelaide, and University of St Andrews, Scotland, Professor Brant Gibson from RMIT University and Dr Antony Orth from the National Research Council of Canada were also co-authors on this research, which published its findings in the Journal of Assisted Reproduction and Genetics.
Founded in 2019 and headquartered in Adelaide, Australia, Fertilis is a medtech startup developing ground-breaking micro medical devices that transform lives. The company’s technology automates the IVF process and increases success rates. It can also play a role in the discovery of new treatments for a range of other chronic conditions such as cancer, diabetes and Cystic Fibrosis.
Fertilis’s pioneering 3D printed medical technology has been more than 20 years in the making. In the late 1990s, Professor Jeremy Thompson first developed an idea to automate IVF. During a sabbatical at RMIT University and the University of Melbourne in 2017, Professor Thompson collaborated with co-members of the Centre for Nanoscale Biophotonics to develop his micro pod design, which was ultimately created using a 3D printer. Working with Professor David Gardner and building upon his involvement over many years, Professor Thompson and his team tweaked and tested the design. The more the technology evolved, the broader its potential became. Serial entrepreneur Marty Gauvin joined Fertilis as CEO in 2019 to help commercialize this technology and make it accessible to millions of people around the world.
Professor Jeremy Thompson, Co-Founder and Chief Scientific Officer, Fertilis. Email: firstname.lastname@example.org
Eoghan Dillon, Account Manager, 150Bond. Email: email@example.com
Dr Kylie Dunning, Hospital Research Foundation Fellow, Robinson Research Institute, University of Adelaide. Email: firstname.lastname@example.org
Lee Gaskin, Senior Media and Communications Officer, University of Adelaide Email: email@example.com